Interferon-alpha-2b + ribavirin for the treatment of chronic hepatitis C in non-responders to interferon-alpha-monotherapy.
The efficacy of a therapy with interferon-alpha-2b and ribavirin in patients with hepatitis C not responding to the initial treatment remains controversial. Objective of the present study was to determine the efficacy of a combination therapy with 3 MU interferon-alpha thrice weekly and 1,000-1,200 mg ribavirin daily for six months in an open label trial. 44 consecutive patients (genotype 1: 79.5%) who had been previously treated with a minimum dose of 3 MU interferon-alpha thrice weekly for at least three months were monitored. Sustained response was defined as virological response with clearance of HCV-RNA after a follow-up period of six months after the end of therapy. A significant decrease of the mean levels of AST (34.3 +/- 27.6 vs. 16.4 +/- 13.5 U/L) and ALT (59.6 +/- 48.8 vs. 23.2 +/- 20.7 U/L) was observed. In 15/44 patients (34.1%) a virological end-of-treatment response was evident. 8/44 patients (18.2%) achieved a sustained response. In 33.3% of the previous non-responders biochemical response with normal aminotransferases, but no virological response was evident. A significant decrease of the mean hemoglobin level was observed during therapy (12.0 +/- 1.7 vs. 14.6 +/- 1.0 g/dl; p < 0.005), which returned to the pretreatment values after the end of treatment (14.4 +/- 1.6 g/dl; n.s.). In ten patients (22.7%) decrease of hemoglobin levels < 10 g/dl led to a dose reduction of ribavirin. This study--in agreement to recently published data--provides evidence for the efficacy of the combination therapy with interferon-alpha-2b and ribavirin in a relevant subset of non-responders to interferon-alpha. Therapeutic nihilism should be reevaluated in non-responders to interferon-alpha.